Core Viewpoint - Weigao Co., Ltd. has successfully obtained the MDSAP certification, enhancing its international market expansion capabilities and solidifying its leading position in the medical system solutions sector [1][2]. Financial Projections - The company is projected to achieve revenues of 135.41 billion, 149.60 billion, and 163.01 billion CNY for the years 2025 to 2027, with corresponding net profits of 20.76 billion, 23.57 billion, and 26.05 billion CNY, resulting in PE ratios of 12X, 10X, and 9X respectively [1]. MDSAP Certification Impact - The MDSAP certification, recognized by regulatory bodies in the US, Australia, Brazil, Canada, and Japan, allows manufacturers to streamline their quality management system audits, significantly reducing time and resource costs associated with multiple country certifications [2]. Product Development and Market Strategy - The company is focusing on enhancing its product matrix by transitioning from low-cost to high-cost/specialized products, with plans to approve over 100 new products in the next three years [2]. - In the orthopedic sector, the company is expanding into new materials, regenerative rehabilitation, smart assistance, and 3D printing, particularly in minimally invasive spine and pain management areas [2]. - The interventional segment has plans to shift some main products to mainland production, with upcoming product launches and academic seminars for Cleaner Vac [2]. - The pharmaceutical packaging segment is developing new production lines for pre-filled syringes and automatic injection pens, expected to commence production in 2026 [2]. - The blood management segment anticipates exceeding a total production capacity of 100 million blood bags by 2025, with an additional 20 million sets of overseas capacity planned for next year [2]. International Revenue Performance - In the first half of 2025, the company reported overseas revenues of 16.24 billion CNY, a year-on-year increase of 3.98%, accounting for 24.44% of total revenue, with significant growth in the US and EMEA regions [3]. - The company has made strategic acquisitions in recent years, including Argon, GHC Healthcare, and Rad Source, to enhance its overseas platform integration and realize synergies [3].
东北证券:予威高股份(01066)“买入”评级 通过MDSAP认证助力产品加速出海